Evidence-Based Pharmacologic Management of Pulmonary Arterial Hypertension

Clinical Therapeutics

Volumn 29, Issue 10, 2007, Pages 2134-2153

  Benedict, Neal ^a   Seybert, Amy ^a   Mathier, Michael A ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

bosentan; epoprostenol; prostacyclin; pulmonary arterial hypertension; sildenafil; treprostinil

Indexed keywords

ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CONTRACEPTIVE AGENT; CYCLOSPORIN; DIGITALIS; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; GLIBENCLAMIDE; ILOPROST; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL; UNIPROST; VASODILATOR AGENT;

ABDOMINAL DISCOMFORT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BRAIN ISCHEMIA; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EVIDENCE BASED MEDICINE; EXERCISE; FLUSHING; HAND PARESTHESIA; HEADACHE; HEART PALPITATION; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOTENSION; ISCHEMIA; JAW PAIN; LIVER FUNCTION; LOOSE FECES; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MEDLINE; MONOTHERAPY; NAUSEA; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PNEUMONIA; PNEUMOTHORAX; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; SIX MINUTE WALK TEST; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SYNCOPE; TACHYCARDIA; THORAX PAIN; THROMBOSIS; VOMITING; WORLD HEALTH ORGANIZATION;

CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS; RECEPTORS, ENDOTHELIN;

EID: 36248950177     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.10.009     Document Type: Article

References (62)

1. D'Alonzo G., Barst R., Ayres S., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
2. Rich S., Dantzker D., Ayres S., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107 (1987) 216-223
3. Simonneau G., Galie N., Rubin L., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 Suppl 12 (2004) 5S-12S
4. Newman J., Wheeler L., Lane K., et al. Mutation in the gene for bone morphogenic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 345 (2001) 319-324 [published corrections appear in
5. Newman J., Wheeler L., Lane K., et al. Mutation in the gene for bone morphogenic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 345 (2001) 1506
6. Newman J., Wheeler L., Lane K., et al. Mutation in the gene for bone morphogenic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 346 (2002) 1258 ]
7. Newman J., Fanburg B., Archer S., et al., National Heart, Lung and Blood Institute/Office of Rare Diseases. Pulmonary arterial hypertension: Future directions: Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 109 (2004) 2947-2952
8. McGoon M., Gutterman D., Steen V., et al., American College of Chest Physicians. Screening, early detection and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 Suppl 1 (2004) 14S-34S
9. Badesch D., Abman S., Ahearn G., et al., American College of Chest Physicians. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 Suppl 1 (2004) 35S-62S
10. In: Rich S. (Ed). Executive Summary from the World Symposium on Primary Pulmonary Hypertension (September 6-10, 1998) Evian, France
11. Borg G. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14 (1982) 377-381
12. Miyamoto S., Nagaya N., Satoh T., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161 (2000) 487-492
13. Rubin L., and Badesch D. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med 143 (2005) 282-292
14. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 (2005) 3105-3111
15. Rich S., Kaufmann E., and Levy P. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 (1992) 76-81
16. Christman B., McPherson C., Newman J., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 (1992) 70-75
17. Tuder R., Cool C., Geraci M., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159 (1999) 1925-1932
18. Flolan (epoprostenol) [package insert] (2002), GlaxoSmithKline, Research Triangle Park, NC
19. Rubin L., Mendoza J., Hood M., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112 (1990) 485-491
20. Barst R., Rubin L., Long W., et al., Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-302
21. Badesch D., Tapson V., McGoon M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
22. Highland K., Strange C., Mazur J., and Simpson K. Treatment of pulmonary arterial hypertension: A preliminary decision analysis. Chest 124 (2003) 2087-2092
23. Remodulin (treprostinil) [package insert] (2006), United Therapeutics Corporation, Silver Spring, Md
24. Simonneau G., Barst R., Galie N., et al., Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A doubleblind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
25. McLaughlin V., Gaine S., Barst R., et al., Treprostinil Study Group. Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharm 41 (2003) 293-299
26. Ventavis (iloprost) [package insert] (2006), Actelion Pharmaceuticals US, Inc, South San Francisco, Calif
27. Hoeper M., Schwarze M., Ehlerding S., et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342 (2000) 1866-1870
28. Olschewski H., Simonneau G., Galie N., et al., Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
29. Opitz C., Wensel R., Winkler J., et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 26 (2005) 1895-1902
30. Opitz C., Wensel R., Bettmann M., et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 24 (2003) 356-365
31. Galie N., Humbert M., Vachiery J., et al., Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39 (2002) 1496-1502
32. Barst R., McGoon M., McLaughlin V., et al., Beraprost Study Grop. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 2119-2125 [published correction appears in
33. Barst R., McGoon M., McLaughlin V., et al., Beraprost Study Grop. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 42 (2003) 591 ]
34. Weber C., Schmitt R., Birnboeck H., et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60 (1996) 124-137
35. Barst R., Langleben D., Frost A., et al., STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Resp Crit Care Med 169 (2004) 441-447
36. Barst R., Langleben D., Badesch D., et al., STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin- A receptor antagonist sitaxsentan. J Am Coll Cardol 47 (2006) 2049-2056
37. Ambrisentan (Letairis) [package insert] (2007), Gilead Sciences, Inc, Foster City, Calif
38. Tracleer (bosentan) [package insert] (2007), Actelion Pharmaceuticals US, Inc, South San Francisco, Calif
39. Channick R., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo-controlled study. Lancet 358 (2001) 1119-1123
40. Rubin L., Badesch D., Barst R., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903 [published correction appears in
41. Rubin L., Badesch D., Barst R., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 1258 ]
42. Revatio (sildenafil) [manufacturer information] (2005), Pfizer Inc, New York, NY
43. Zhao L., Mason N., Morrell N., et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104 (2001) 424-428
44. Sastry B., Narasimhan C., Reddy N., and Raju B. Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43 (2004) 1149-1153
45. Wilkins M., Paul G., Strange J., et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 171 (2005) 1292-1297
46. Hoeper M., Oudiz R., Peacock A., et al. End points and clinical trial designs in pulmonary arterial hypertension: Clinical and regulatory perspectives. J Am Coll Cardiol 43 Suppl 12S (2004) 48S-55S
47. Galie N., Ghofrani H., Torbicki A., et al., Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157 [published correction appears in
48. Galie N., Ghofrani H., Torbicki A., et al., Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 354 (2006) 2400-2401 ]
49. Michelakis E., Tymchak W., Noga M., et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108 (2003) 2066-2069
50. Hoeper M., Taha N., Bekjarova A., et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 22 (2003) 330-334
51. Humbert M., Barst R., Robbins I., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24 (2004) 353-359
52. Ghofrani H., Wiedemann R., Rose F., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136 (2002) 515-522
53. Stiebellehner L., Petkov V., Vonbank K., et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 123 (2003) 1293-1295
54. Hoeper M., Faulenbach C., Golpon H., et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 24 (2004) 1007-1010
55. McLaughlin V., Oudiz R., Frost A., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174 (2006) 1257-1263
56. Hoeper M., Markevych I., Spiekerkotter E., et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26 (2005) 858-863
57. Kothari S., and Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J 54 (2002) 404-409
58. Bhatia S., Frantz R., Severson C., et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 78 (2003) 1207-1213
59. Kuhn K., Byrne D., Arbogast P., et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 167 (2003) 580-586
60. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
61. McLaughlin V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
62. Frost AE. An update on improving survivability in pulmonary hypertension. http://www.medscape.com/viewarticle/508767. Accessed October 15, 2007.